Advanced search
Publication Cover
Leukemia & Lymphoma Volume 50, 2009 - Issue 5
Submit an article Journal homepage
173
Views
27
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab

Dr. Wen-Kai Weng Division of Blood and Marrow Transplantation, Department of MedicineCorrespondence[email protected]
&
Ronald Levy Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
Pages 723-727 | Received 28 Jan 2009, Accepted 15 Feb 2009, Published online: 21 Jul 2009

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Riad Abès, Charles-Antoine Dutertre, Lauren Agnelli & Jean-Luc Teillaud. (2009) Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target. Expert Review of Clinical Immunology 5:6, pages 735-747.
Read now

Articles from other publishers (26)

Daniele Lavacchi, Ida Landini, Gabriele Perrone, Giandomenico Roviello, Enrico Mini & Stefania Nobili. (2022) Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge. Pharmacology & Therapeutics 229, pages 107924.
Crossref
Kavina Shah, Mark Cragg, Maria Leandro & Venkat Reddy. (2021) Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. Biologicals 69, pages 1-14.
Crossref
Matthew J. Barth & Stanton C. Goldman. 2019. Resistance to Targeted Therapies in Lymphomas. Resistance to Targeted Therapies in Lymphomas 27 55 .
David Zahavi, Dalal AlDeghaither, Allison O’Connell & Louis M Weiner. (2018) Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antibody Therapeutics 1:1, pages 7-12.
Crossref
Rika Fujii, Jeffrey Schlom & James W. Hodge. (2018) A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab. Journal of Neurosurgery 128:5, pages 1419-1427.
Crossref
Juliet C. Gray & Paul M. Sondel. 2018. Immunotherapy for Pediatric Malignancies. Immunotherapy for Pediatric Malignancies 65 78 .
Caroline Jochems, Sarah R. Tritsch, Samuel Troy Pellom, Zhen Su, Patrick Soon-Shiong, Hing C. Wong, James L. Gulley & Jeffrey Schlom. (2017) Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824). Oncotarget 8:43, pages 75217-75231.
Crossref
Caroline Jochems, James W. Hodge, Massimo Fantini, Kwong Y. Tsang, Amanda J. Vandeveer, James L. Gulley & Jeffrey Schlom. (2017) ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. International Journal of Cancer 141:3, pages 583-593.
Crossref
Caroline Jochems, James W. Hodge, Massimo Fantini, Rika Fujii, Y. Maurice MorillonIIII, John W. Greiner, Michelle R. Padget, Sarah R. Tritsch, Kwong Yok Tsang, Kerry S. Campbell, Hans Klingemann, Laurent Boissel, Shahrooz Rabizadeh, Patrick Soon-Shiong & Jeffrey Schlom. (2016) An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele. Oncotarget 7:52, pages 86359-86373.
Crossref
Duo Liu, Yuyang Tian, Donglin Sun, Haiming Sun, Yan Jin & Mei Dong. (2016) The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis. Annals of Hematology 95:9, pages 1483-1490.
Crossref
Simone Battella, Maria Christina Cox, Angela Santoni & Gabriella Palmieri. (2016) Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. Journal of Leukocyte Biology 99:1, pages 87-96.
Crossref
Chantal E. Hargreaves, Matthew J. J. Rose-Zerilli, Lee R. Machado, Chisako Iriyama, Edward J. Hollox, Mark S. Cragg & Jonathan C. Strefford. (2015) Fcγ receptors: genetic variation, function, and disease. Immunological Reviews 268:1, pages 6-24.
Crossref
D. Pérez-Callejo, J. González-Rincón, A. Sánchez, M. Provencio & M. Sánchez-Beato. (2015) Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas. Cancer Treatment Reviews 41:8, pages 680-689.
Crossref
Juan Du, Sandra Lopez-Verges, Brandelyn N. Pitcher, Jeffrey Johnson, Sin-Ho Jung, Lili Zhou, Katharine Hsu, Myron S. Czuczman, Bruce Cheson, Lawrence Kaplan, Lewis L. Lanier & Jeffrey M. Venstrom. (2014) CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells. Cancer Immunology Research 2:9, pages 878-889.
Crossref
Venkat Reddy & Maria Leandro. (2014) Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy?. International Journal of Clinical Rheumatology 9:3, pages 279-293.
Crossref
Marije B. Overdijk, Sandra Verploegen, Wim K. Bleeker & Paul W.H.I. Parren. 2014. Antibody Fc. Antibody Fc 239 255 .
Emily L. Williams, Sean H. Lim, Stephen A. Beers, Peter W. Johnson, Jonathan C. Strefford, Martin J. Glennie & Mark S. Cragg. 2013. Resistance to Immunotherapeutic Antibodies in Cancer. Resistance to Immunotherapeutic Antibodies in Cancer 49 71 .
Divi Cornec, Adrian Tempescul, Solène Querellou, Pascal Hutin, Jacques-Olivier Pers, Christophe Jamin, Boutahar Bendaoud, Christian Berthou, Yves Renaudineau & Pierre Youinou. (2011) Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy. Annals of Hematology 91:5, pages 715-721.
Crossref
Sean H. LimAndrew T. VaughanMargaret Ashton-Key, Emily L. WilliamsSandra V. DixonH. T. Claude ChanStephen A. BeersRuth R. FrenchKerry L. CoxAndrew J. Davies, Kathleen N. Potter, C. Ian MockridgeDavid G. Oscier, Peter W. M. Johnson, Mark S. CraggMartin J. Glennie. (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118:9, pages 2530-2540.
Crossref
Steven P. Treon, Guang Yang, Christine Hanzis, Leukothea Ioakimidis, Sigitas J. Verselis, Edward A. Fox, Lian Xu, Zachary R. Hunter, Hsiuyi Tseng, Robert J. Manning, Christopher J. Patterson, Patricia Sheehy & Barry Turnbull. (2011) Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia. British Journal of Haematology 154:2, pages 223-228.
Crossref
Robert A. Baiocchi, Lapo Alinari, Mark E. Lustberg, Thomas S. Lin, Pierluigi Porcu, Xiaobai Li, Jeffrey S. Johnston, John C. Byrd & Kristie A. Blum. (2010) Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 117:11, pages 2442-2451.
Crossref
Yun Zhuang, Wei Xu, Yunfeng Shen & Jianyong Li. (2010) Fcγ Receptor Polymorphisms and Clinical Efficacy of Rituximab in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 10:5, pages 347-352.
Crossref
Aleth Perdriger, Dorothée Rihouey & Marie-Clémence Verdier. (2010) Pharmacogénomique et traitement de la polyarthrite rhumatoïde. Revue du Rhumatisme Monographies 77:4, pages 341-345.
Crossref
Philip Downey. (2010) Profile of Ronald Levy. Proceedings of the National Academy of Sciences 107:29, pages 12745-12746.
Crossref
J. Lejeune, G. Thibault, G. Cartron, M. Ohresser & H. Watier. (2010) Rôle des récepteurs à la portion Fc des IgG (FcγRs) dans l’activité des anticorps thérapeutiques. Bulletin du Cancer 97:5, pages 511-522.
Crossref
Wen-Kai WengRobert S. NegrinPhilip LavoriSandra J. Horning. (2010) Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 28:2, pages 279-284.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.